{"meshTags":["Female","Risk Factors","Humans","Chorionic Gonadotropin","Estriol","Maternal Age","Neural Tube Defects","Pregnancy","alpha-Fetoproteins","Down Syndrome","Fetal Diseases","Ultrasonography, Prenatal","Amniocentesis","Algorithms","Prenatal Diagnosis"],"meshMinor":["Female","Risk Factors","Humans","Chorionic Gonadotropin","Estriol","Maternal Age","Neural Tube Defects","Pregnancy","alpha-Fetoproteins","Down Syndrome","Fetal Diseases","Ultrasonography, Prenatal","Amniocentesis","Algorithms","Prenatal Diagnosis"],"genes":["alpha-fetoprotein","human chorionic gonadotropin"],"organisms":["9606","9606","9606"],"publicationTypes":["Journal Article"],"abstract":"Maternal serum screening (MSS) measures three serum markers: alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol, from which the risk of fetal Down syndrome or open neural tube defect is calculated. Initially, 8% of women will have positive results. I present a protocol for investigating these women. Family physicians should be informed about MSS so they can give their patients information and guidance.","title":"Maternal serum screening.","pubmedId":"7524838"}